Verastem
Verastem, a development-stage biopharma, advances RAF/MEK and FAK inhibitors (Avutometinib/Defactinib) for RAS-driven cancers, backed by trials and collaborations with Chugai, Pfizer, and Amgen.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 78
- HQ: Needham
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.